General Licence versus Medical Device Commission Exclusion List Review in Iran

1. Key takeaways

Iran operates a triage mechanism of general licence plus exclusion list: routine products proceed under the general licence, and only items that fall on the exclusion list of the Medical Device Commission trigger a full technical review. The judgment of GRZAN is that the value of this mechanism lies in the fact that it can be contested — through upfront pathway argumentation and reference-country evidence, a company has a reasonable probability of keeping its product inside the general licence channel. In practical terms, this means the pathway question is won or lost at the very first pages of the dossier, before any technical content is read. Conversely, if the dossier cannot articulate the applicable pathway at the very opening, the probability of being defaulted into case-by-case review rises markedly.

• Most routine devices are covered by the general licence, and the exclusion list is the dividing line that determines whether full technical review is required.
• Items on the exclusion list must undergo complete technical review by the Medical Device Commission, which is a materially heavier and slower process than the general route.
• Pathway argumentation belongs at the opening of the dossier, supported by the risk class determination and by reference-country evidence placed where the reviewer sees it first.
• Reference-country approvals and documented marketing history are the most effective instruments for arguing that a product has routine attributes.
• For Class C and Class D devices, case-by-case review is unavoidable, so the effort should shift to shortening the number of review rounds rather than escaping the channel.
• Whether a specific item sits on the exclusion list must be verified with IMED through the local entity, because the Iranian official document number has not been published in public channels.
• Written records of every pathway communication with the authority serve as the evidentiary basis if the triage decision is disputed later.

2. Legal basis

The triage mechanism itself is documented through public industry databases that record the Iranian pathway: most routine devices are subject to the general licence, while items on the exclusion list must pass the complete technical review of the Medical Device Commission. This division of labour between the light channel and the heavy channel is what gives the system its practical shape. The Iranian official document number for this mechanism has not been released through public channels, and this is a practical estimate.

The statutory anchor is the Law Concerning Regulations of Medical, Laboratory, Pharmaceutical and Food and Beverage Affairs, recorded in FAOLEX as LEX-FAOC227692, dated 1955-06-20, Article 3. This provision establishes the principle that medical affairs are subject to prior authorisation, which is the legal foundation on which any licence regime, light or heavy, ultimately rests.

The forward-looking layer is clause B of Article 72 of Chapter 14 of the Seventh National Development Plan Law of the Islamic Republic of Iran, which concerns the issuance of registration certificates, market access permits and joint production quality certificates in the regional context. It signals that the pathway architecture is being aligned with a broader recognition strategy rather than standing in isolation.

3. Expert insights

Insight 1: triage is the inevitable product of resource constraints. Iran’s review resources are limited, and any regulatory system operating under such constraints will design a triage mechanism of exactly this kind. Once this is understood, the corporate strategy becomes clear: the productive response is not to complain that review is slow, but to actively reduce the review complexity of one’s own product. Every element of the dossier that lowers the apparent complexity of the case moves it toward the lighter channel, and every unexplained anomaly does the opposite.

Insight 2: reference-country evidence is the most effective triage tool. Products that already hold CE or FDA approval carry a natural advantage when arguing their routine attributes, because the reviewer receives an external anchor for the claim. GRZAN recommends attaching reference-country approvals and marketing history at the opening of the dossier rather than burying this material in an appendix, because the reviewer’s first impression of the case determines how the pathway question is framed from the outset.

Insight 3: case-by-case review is not inherently unacceptable. For Class C and Class D products, case-by-case review is the necessary path, and no amount of argumentation will change that classification. When a company knows in advance that the heavier channel cannot be avoided, the effort should shift toward shortening the number of review rounds — that is, submitting everything correctly the first time — rather than wasting resources on trying to escape the channel altogether.

4. Practical recommendations

• Open with pathway argumentation: state on the first page of the dossier that the product applies under the general licence, and attach the risk class determination together with reference-country evidence so the framing is set immediately.
• Front-load reference-country evidence: place CE/FDA certificates and marketing history at the front of the dossier, not in the appendix, because position influences how the reviewer weighs the evidence.
• For Class C/D, aim for one-pass submission: complete an item-by-item self-check against the review points checklist before submitting, with the explicit target of passing in a single round.
• Keep written records of triage communications: document in writing the outcome of every communication with the competent authority on the applicable pathway, as the evidentiary basis for any later dispute over the routing decision.

5. Verification checklist

• □ Pathway argumentation has been completed at the opening of the dossier and reference-country evidence attached
• □ It has been confirmed whether the item to be declared sits on the exclusion list (verified with IMED by the local entity)
• □ For Class C/D, a one-pass self-check against the review points has been completed
• □ The outcome of pathway communications has been archived in writing
• □ The dossier structure has been rearranged so that argumentation comes first and evidence follows

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Iranian market. Our team manages IFDA registration applications, prepares reference-country dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com